Paxlovid, a Pfizer-developed anti-covid medicine that is the first anti-covid treatment licensed in the United States in oral tablet form, received emergency approval from the US Food and Drug Administration (FDA). Paxlovid was licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) in London shortly after. The first supply of the medication recently arrived…
Celon Pharma has secured a contract with the Medical Research Agency for the execution and finance of a commercial clinical trial project called “TransformRNA – mRNA Therapeutics generation platform” to create breakthrough therapeutic solutions using RNA technology. The project’s overall cost is PLN 141.6 million, with co-financing totaling approximately PLN 83.5m. As part of the…
The government’s list of legislative works included a draft of the covid regulation. It expects that the limits will be further tightened and extended until the end of January 2022. There will also be certain modifications that the Ministry of Health has not yet notified the public about. The document confirms the extension of the existing and…
The Minister of Health has announced new measures to combat the pandemic and tighten restrictions. These include mandatory testing for household members of people with COVID-19, regardless of their covid certification, mandatory vaccination for three occupational groups, and the right to check coronavirus tests by employers. The latest steps to battle the pandemic, according to…
Although the Minister of Health talks about reaching the moment of solstice of the fourth wave of Covid-19 infections, the epidemic situation in Poland does not inspire any optimism. Hospitals are already fully occupied and the growing number of infected people requiring hospitalisation is steadily increasing. More wards with covid beds are already opening. However,…
Clinical trials on the efficacy of a novel COVID-19 drug Paxlovid will enlist 90 participants. Pfizer, a pharmaceutical corporation based in the United States, has been granted permission by Russian authorities to test Paxlovid. The medicine will be studied in Russia until March 2023, although it is known that roughly 7,000 people in other countries have already begun…
Preliminary results from an experimental study of Pfizer’s new drug for Covid-19 are very promising, with an 89% efficacy rate in reducing the risk of hospitalisation and death. This follows a product from Merck that will reduce risk among patients predisposed to a severe form of Covid-19. During ongoing clinical trials of Paxlovid, the drug…
On November 2, registration for the COVID-19 booster vaccination for adults began, provided it has been at least six months since receiving the full vaccination. As of mid-September, only people over the age of 50, medical personnel in contact with patients, and people who are immunocompromised could make appointments for the booster vaccination. The booster shot…
A new SARS-CoV-2 sequencing method has helped detect a Delta variant that could not be identified using older NGS technology. Currently, Polish startup genXone is using the latest technology in the field of diagnostics, thanks to which approximately 70% of coronaviruses in Poland are being sequenced. As Professor Jakub Swadźba, President of Diagnostyka SA and…
New variants of Covid-19 mean that scientists are constantly looking for solutions to effectively protect as many people as possible from serious complications when infected with the virus. BioNTech’s CEO has announced that a new vaccine formulation needs to be developed to protect more effectively against new mutations of the disease, which are likely to…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.